Drug intelligence / Profile preview

EPI100

Development stage: Preclinical
Modality: Small Molecules
Administration: Intrathecal, Intraosseous, Intravenous

Overview

EPI100 is a non-specific identifier that refers to different drug-related entities in the provided context. It is used to denote a 100 mcg dose of intrathecal epinephrine, which is studied for prolonging motor block duration in lower limb arthroplasty. Additionally, 'EPI100' refers to the 1:100,000 concentration of epinephrine when combined with 4% articaine for intraosseous injections in dental procedures. The term 'Epi100' (with a lowercase 'i') also refers to a 100 mg/m2 dose of epirubicin in oncology. Furthermore, 'EPI100' is identified as an E. coli bacterial strain in one publication.

Targets

VHL (Von Hippel–Lindau tumor suppressor protein)TET3 (Tet methylcytosine dioxygenase 3)

Beyond the preview

Go deeper on EPI100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI100.

Explore the full profile